NKTR News and Press, Nektar Therapeutics From 02/28/23

Nektar Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results PR Newswire SAN FRANCISCO , Feb. 28, 2023 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter and full year ended December 31, ...

Summary Nektar announced that the ISLAND study of rezpeg in lupus failed to meet its primary endpoint and that Lilly would not be advancing the drug into Phase III studies. Rezpeg continues to show concerning tolerability issues, and I expect Lilly to walk away from the program entirely...

Nektar Therapeutics ( NASDAQ: NKTR ) lost ~46% on Friday as Jefferies downgraded the biopharma to Underperform from Hold after its Phase 2 trial for systemic lupus erythematosus (SLE) candidate Rezpeg failed to meet the main goal. The analyst Roger Song argued that Eli Lilly (...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Bukhta Yurii / Shutterstock.com Nektar Therapeutics (NASDAQ: NKTR ) stock is taking a beating on Friday following the release of Phase 2 clinical trial data . This Phase 2 study had Nektar Therapeutics te...

Nektar Therapeutics ( NASDAQ: NKTR ) has plunged 29% in after-hours trading after reporting that a phase 2 trial for a lupus candidate failed to meet its primary endpoint. The asset, rezpegaldesleukin (REZPEG), is a potential first-in-class selective regulatory T-cell inducin...

Nektar Therapeutics Announces Phase 2 Topline Data for Rezpegaldesleukin in Patients with Systemic Lupus Erythematosus PR Newswire Improvement in SLEDAI-2K score observed as compared to placebo, although study did not meet primary endpoint Clinically meaningful impro...

Summary Nektar is trying to come back from the crushing failure of bempeg, and it has two lead candidates and $500M in cash to drive the effort. The next major clinical milestone is the Phase II read-out of ISLAND in lupus; success could drive $3/share of upside and build credibility fo...

Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Nektar Therapeutics (Nasdaq: NKTR) concerning the Company and its directors’ and officers’ possible violations of state laws. If you own Nektar Therapeutics stock, would like to learn more about...

Nektar Therapeutics' President and CEO, Howard Robin, To Present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA PR Newswire SAN FRANCISCO , Jan. 4, 2023 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive O...

Nektar Announces Poster Presentations at the 64th American Society of Hematology (ASH) Annual Meeting PR Newswire -- Unveils Trial Design for Nektar Phase 2/3 Study Combining NKTR-255 with CAR-T Therapies -- -- Presents First Data for NKTR-255 in Combination...